Alpha 2.0
Login Register
» Authors » Nobuhisa Ishikawa

Nobuhisa Ishikawa

Explore the profile of Nobuhisa Ishikawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 115
Citations 2639
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Nobuoki Kohno
Noboru Hattori
Kazunori Fujitaka
Yataro Daigo
Yusuke Nakamura
Kosuke Hamai
Masahiro Yamasaki
Hiroshi Iwamoto
Akihito Yokoyama
Yasushi Horimasu
Published In
Cancer Res
Respir Investig
Ther Adv Med Oncol
Intern Med
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, et al.
Ther Adv Med Oncol . 2025 Feb; 17:17588359251318850. PMID: 39957806
Background: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. Objective: We aimed to evaluate the clinical characteristics...
2.
Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)
Nagase H, Kobayashi K, Toma-Hirano M, Suzukawa M, Harada N, Masaki K, et al.
Allergol Int . 2025 Jan; PMID: 39848869
Background: Although randomized controlled trials (RCT) have demonstrated the efficacy of mepolizumab for asthma, they have excluded certain patient subgroups. To bridge the gap between RCT and real-world practice, the...
3.
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study
Furuya N, Tsubata Y, Hotta T, Yokoyama T, Yamasaki M, Ishikawa N, et al.
Cancer Med . 2025 Jan; 14(1):e70568. PMID: 39783855
Background: Cancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of...
4.
Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study
Masuda T, Tsubata Y, Hata K, Horie M, Kiura K, Kanaji N, et al.
Thorac Cancer . 2024 Oct; 15(34):2408-2417. PMID: 39415454
Introduction: Studies have shown the antitumor efficacy of immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). However, it is unclear whether the...
5.
Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, et al.
Respir Investig . 2024 Oct; 62(6):1137-1141. PMID: 39366122
Background: There is a dearth of studies on the efficacy and safety of the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) in treating epidermal growth factor receptor (EGFR) mutation-positive...
6.
A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer
Hamai K, Katsura R, Miyake S, Fujita S, Tada S, Hirakawa T, et al.
Cancer Control . 2024 Aug; 31:10732748241274615. PMID: 39120923
Introduction: Docetaxel plus ramucirumab (DTX + RAM) therapy is a standard treatment for previously treated lung cancer, but many adverse events have been reported. This retrospective study was conducted to...
7.
Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study
Shinkai M, Ota S, Ishikawa N, Tanimoto T, Suzuki H, Abe S, et al.
Respir Investig . 2024 Jun; 62(4):717-725. PMID: 38823191
Background: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza virus are responsible for acute respiratory tract infections (ARTIs) in adults. We assessed the clinical burden of RSV, hMPV and...
8.
D-dimer cut-off value for predicting venous thromboembolism at the initial diagnosis in Japanese patients with advanced lung cancer
Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Masuda T, et al.
Jpn J Clin Oncol . 2024 May; 54(9):1032-1036. PMID: 38769814
Objective: Cancer is a well-known risk factor for venous thromboembolism. The D-dimer level is used to predict venous thromboembolism; however, reports on an appropriate D-dimer cut-off value in Japanese patients...
9.
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, et al.
J Cancer Res Clin Oncol . 2024 Feb; 150(2):89. PMID: 38347279
Purpose: Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were...
10.
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, et al.
Lung . 2024 Jan; 202(1):63-72. PMID: 38265672
Purpose: This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). Methods: This multicenter retrospective...